Jon Wigginton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity GlobeNewswire April 09, 2024 SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE...

SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing multifunctiona...

- BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity - - BPT331, a PD1-IL2

- Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony...

- Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission